What is new in perinatal HIV prevention?

Mary Glenn Fowler, Patricia Flynn, Jim Aizire

Research output: Contribution to journalReview article

Abstract

Purpose of review: The purpose of this review is to describe recent clinical trial, laboratory and observational findings that highlight both the progress that can be achieved in elimination of new pediatric infections in international clinical trial settings among HIV-infected breastfeeding women while also describing recent safety concerns related to currently used antiretroviral regimens. The article will also address the ongoing adherence challenges for HIV-infected mothers in taking their antiretroviral drugs. This information is timely and relevant as new regimens are being considered for both prevention of mother-to-child transmission (PMTCT) of HIV and HIV treatment options worldwide. Recent findings: The main themes described in this article include both efficacy of different antiretroviral therapy (ART) regimens currently being rolled out internationally for PMTCT as well as safety findings from recent research including a large multisite international trial, PROMISE. Summary: The findings from the IMPAACT PROMISE trial as well as other recent trial and observational findings suggest that while progress has been steady in reducing PMTCT worldwide, the goal of virtual elimination of pediatric HIV worldwide will require careful attention to optimizing safety of new regimens which are less dependent on maternal daily ART adherence and safer in preventing certain toxicities.

Original languageEnglish (US)
Pages (from-to)144-151
Number of pages8
JournalCurrent Opinion in Pediatrics
Volume30
Issue number1
DOIs
StatePublished - Feb 1 2018

Fingerprint

Mothers
HIV
Safety
Clinical Trials
Pediatrics
Breast Feeding
Therapeutics
Infection
Research
Pharmaceutical Preparations

Keywords

  • adverse safety outcomes
  • current prevention of mother-to-child transmission efficacy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

What is new in perinatal HIV prevention? / Fowler, Mary Glenn; Flynn, Patricia; Aizire, Jim.

In: Current Opinion in Pediatrics, Vol. 30, No. 1, 01.02.2018, p. 144-151.

Research output: Contribution to journalReview article

@article{b69cc315734c4dc89df0434bb8d7f4a3,
title = "What is new in perinatal HIV prevention?",
abstract = "Purpose of review: The purpose of this review is to describe recent clinical trial, laboratory and observational findings that highlight both the progress that can be achieved in elimination of new pediatric infections in international clinical trial settings among HIV-infected breastfeeding women while also describing recent safety concerns related to currently used antiretroviral regimens. The article will also address the ongoing adherence challenges for HIV-infected mothers in taking their antiretroviral drugs. This information is timely and relevant as new regimens are being considered for both prevention of mother-to-child transmission (PMTCT) of HIV and HIV treatment options worldwide. Recent findings: The main themes described in this article include both efficacy of different antiretroviral therapy (ART) regimens currently being rolled out internationally for PMTCT as well as safety findings from recent research including a large multisite international trial, PROMISE. Summary: The findings from the IMPAACT PROMISE trial as well as other recent trial and observational findings suggest that while progress has been steady in reducing PMTCT worldwide, the goal of virtual elimination of pediatric HIV worldwide will require careful attention to optimizing safety of new regimens which are less dependent on maternal daily ART adherence and safer in preventing certain toxicities.",
keywords = "adverse safety outcomes, current prevention of mother-to-child transmission efficacy",
author = "Fowler, {Mary Glenn} and Patricia Flynn and Jim Aizire",
year = "2018",
month = "2",
day = "1",
doi = "10.1097/MOP.0000000000000579",
language = "English (US)",
volume = "30",
pages = "144--151",
journal = "Current Opinion in Pediatrics",
issn = "1040-8703",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - What is new in perinatal HIV prevention?

AU - Fowler, Mary Glenn

AU - Flynn, Patricia

AU - Aizire, Jim

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Purpose of review: The purpose of this review is to describe recent clinical trial, laboratory and observational findings that highlight both the progress that can be achieved in elimination of new pediatric infections in international clinical trial settings among HIV-infected breastfeeding women while also describing recent safety concerns related to currently used antiretroviral regimens. The article will also address the ongoing adherence challenges for HIV-infected mothers in taking their antiretroviral drugs. This information is timely and relevant as new regimens are being considered for both prevention of mother-to-child transmission (PMTCT) of HIV and HIV treatment options worldwide. Recent findings: The main themes described in this article include both efficacy of different antiretroviral therapy (ART) regimens currently being rolled out internationally for PMTCT as well as safety findings from recent research including a large multisite international trial, PROMISE. Summary: The findings from the IMPAACT PROMISE trial as well as other recent trial and observational findings suggest that while progress has been steady in reducing PMTCT worldwide, the goal of virtual elimination of pediatric HIV worldwide will require careful attention to optimizing safety of new regimens which are less dependent on maternal daily ART adherence and safer in preventing certain toxicities.

AB - Purpose of review: The purpose of this review is to describe recent clinical trial, laboratory and observational findings that highlight both the progress that can be achieved in elimination of new pediatric infections in international clinical trial settings among HIV-infected breastfeeding women while also describing recent safety concerns related to currently used antiretroviral regimens. The article will also address the ongoing adherence challenges for HIV-infected mothers in taking their antiretroviral drugs. This information is timely and relevant as new regimens are being considered for both prevention of mother-to-child transmission (PMTCT) of HIV and HIV treatment options worldwide. Recent findings: The main themes described in this article include both efficacy of different antiretroviral therapy (ART) regimens currently being rolled out internationally for PMTCT as well as safety findings from recent research including a large multisite international trial, PROMISE. Summary: The findings from the IMPAACT PROMISE trial as well as other recent trial and observational findings suggest that while progress has been steady in reducing PMTCT worldwide, the goal of virtual elimination of pediatric HIV worldwide will require careful attention to optimizing safety of new regimens which are less dependent on maternal daily ART adherence and safer in preventing certain toxicities.

KW - adverse safety outcomes

KW - current prevention of mother-to-child transmission efficacy

UR - http://www.scopus.com/inward/record.url?scp=85041604216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041604216&partnerID=8YFLogxK

U2 - 10.1097/MOP.0000000000000579

DO - 10.1097/MOP.0000000000000579

M3 - Review article

VL - 30

SP - 144

EP - 151

JO - Current Opinion in Pediatrics

JF - Current Opinion in Pediatrics

SN - 1040-8703

IS - 1

ER -